FIA
CCCC icon

FNY Investment Advisers’s C4 Therapeutics CCCC Stock Holding History

FNY Investment Advisers’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,800
Closed -$49K – 690
2023
Q4 		$49K Buy
+8,800
New +$20.1K 0.05% 186

Other funds holding CCCC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FNY Investment Advisers's CCCC Position: Q1 2024 in Review

FNY Investment Advisers sold out of C4 Therapeutics (CCCC) in Q1 2024, closing a stake of 8,800 shares — an estimated $49K sold.

FNY Investment Advisers first reported a position in CCCC in Q4 2023 and held it in 1 quarter. The position peaked at $49K in Q4 2023. 106 funds tracked by Wall St. Rank hold CCCC as of Q1 2024.

  • FNY Investment Advisers reported no remaining C4 Therapeutics position as of Q1 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 8,800 C4 Therapeutics shares in Q1 2024, an estimated $49K.
  • FNY Investment Advisers first reported a position in C4 Therapeutics in Q4 2023 and held it in 1 quarter.
  • FNY Investment Advisers's C4 Therapeutics position peaked at $49K in Q4 2023.
  • 106 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2024.

Based on FNY Investment Advisers's 13F filing for Q1 2024, filed 3 May 2024.